NCT04676607已完成2 期
SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2020年12月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18-75 years，male
- •ECOG PS：0-1
- •Life expectancy of more than 6 months
- •After surgery or drug castration, testosterone level was < 50 ng / dl. For subject receiving LHRH agonist / antagonist therapy (patients without orchiectomy), the treatment must start at least 4 weeks before the first day of cycle 1 and must be continued throughout the study
- •Failure (radiological or PSA progression) or intolerance of at least one but not more than two taxanes based chemotherapy regimens and novel endocrine therapy (at least one of enzalutamide, apartamide, abitelone or shr3680). If docetaxel regimen used more than once, count as one regimen
- •Disease progressed within 6 months prior to inclusion in the study. Disease progression defined as the occurrence of one or more of the following three items at the same time of castration：
- •① PSA progression，defined as at least twice increases in PSA level (interval time ≥ 1 week, and PSA level at screening should be ≥ 2ng / ml)
- •②Disease progression as defined in RECIST 1.1
- •③Bone disease progression defined by PCWG3，more than 2 new lesions in bone scan
- •Metastatic lesions with radiologica evidence， measurable non-bone target lesions
- •Adequate hepatic, renal, heart, and hematologic functions (no blood transfusion or hematopoietic growth factor treatment within 2 weeks before blood routine screening)：platelets>80×10^9/L，neutrophil>1.5×10^9/L, Hb≥90 g/L,total bilirubin≤1.5×limit of normal(ULN), ALT and AST ≤2.5×ULN（≤5×ULN with liver metastasis），blood urea nitrogen and creatinine≤1.5×ULN
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure
- •Willing to participate in this clinical trial, understand the research procedures and have signed informed consent
排除标准
- •Prior treatment with MEK inhibitors，including trametinib
- •Washout period from the end of any previous anti-tumor treatment (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, androgen receptor inhibitors, CYP-17 inhibitors, 5 α-reductase inhibitors, estrogen, progesterone drugs, etc) to the first administration of the study drug less than 1 week (bicalutamide elution period < 2 weeks)
- •Plant drugs (e.g. Saw Palmetto) or steroids that may reduce PSA levels within 4 weeks, or planned to be used during the trial period (except for temporary steroid drugs for preventing or treating allergies)
- •Plan to receive any other anti-tumor treatment during this trial
- •Last drug administration from other clinical trials within 4 weeks
- •Radiological confirmed tumor foci in the brain
- •Severe bone injury caused by tumor bone metastasis judged by researchers, including severe bone pain with poor control, pathological fracture of important parts and spinal cord compression occurred or expected to occur in recent 6 months
- •History of epilepsy, or the disease that can induce epilepsy within 12 months (including the history of transient ischemic attack, cerebral apoplexy (except for cerebral ischemic foci simply found by imaging examination), brain trauma with disturbance of consciousness and hospitalization）
- •Hypotension (systolic blood pressure < 86mmhg) or uncontrollable hypertension (systolic blood pressure ≥ 150mmhg or diastolic blood pressure ≥ 100mmhg) within 30 days. The blood pressure results were the average value of three consecutive measurements with an interval of more than 2 minutes
- •Active heart disease including severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring drug treatment within 6 months
- •Inability to swallow, chronic diarrhea and intestinal obstruction, or other factors affecting drug administration and absorption
- •History of retinopathy confirmed by ophthalmic examination or neurosensory retinal detachment. Risk factors such as retinal vein thrombosis / occlusion (RVO), central serous retinopathy (CSR) or neovascular macular degeneration
- •IOP > 21mmhg or diagnosed with glaucoma within 4 weeks
- •Active HBV or HCV infection (HBV copies ≥ 10^4 copies / ml, HCV copies ≥ 10^3 copies/ml)
- •History of immunodeficiency (including HIV positive, other acquired and congenital immunodeficiency diseases) or organ transplantation history
- •Not willing to take effective contraceptive measures during the whole study period and within 6 months after the last administration
- •Any accompanying diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease and psychosis) that seriously endanger the safety of patients or affect the patients to complete the study
研究组 & 干预措施
treatment group
Experimental
SHR7390
干预措施: SHR7390 (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 2 years
The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
AE
时间窗: 2 years
The type, frequency, severity, timing, seriousness, and relationship to study therapy
次要结局
- DoR(2 years)
- PSA response rate(2 years)
- Time to prostate specific antigen (PSA) progression(2 years)
- Radiographic Progression Free Survival(rPFS)(2 years)
- OS(2 years)
- Time to skeletal-related events(2 years)
研究者
Hongqian Guo
Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCProstate Cancer MetastaticNCT04603833Jiangsu HengRui Medicine Co., Ltd.150
进行中（未招募）
3 期
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeHormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast CancerNCT04842617Jiangsu HengRui Medicine Co., Ltd.5,274
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer PatientsBreast NeoplasmsMetastasesNCT00080197Eisai Inc.250
已完成
2 期
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeAsthma With Eosinophilic PhenotypeNCT05522439Jiangsu HengRui Medicine Co., Ltd.85
进行中（未招募）
3 期
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaAsthma With Eosinophilic PhenotypeNCT06653322Guangdong Hengrui Pharmaceutical Co., Ltd401